Expression Of CDC25C And CLDN6Proteins In Hepatocellular Carcinoma And Its Clinical Significance

Hepatocellular carcinoma（HCC）is one of the common malignant tumor ofdigestive system and too high incidence of malignant tumors in humans. From aglobal perspective, it is a common malignant disease which has high morbidity andmortality.Acoording to the statistics,the mortality of the live cancer was the thirdplace of malignant tumors. It has high rates of hepatocellular carcinoma in Africa andAsia. In Asia, especially China, it has the higher rates. In China, the morbidity ofprimary liver cancer is the2nd in the cause of malignant tumor death.What,smore,because our country has many HBV patients,most of them belong tohepatocellular carcinoma.In recent years, with the development of medicaltechnology, the improvement of people’s living standards and self-awareness, ourcountry has gained great achievemen in the clinical diagnosis of early and mid-termHCC and treatment.Form nationwide, especially in developed areas, our country hasobtained certain result.But it has great difficulty in treatment, as is often found in thelate.When the patients were cured, the prognosis is poor and the survival time isshorter. Although the patient has the early, medium-term hepatocellular carcinoma,when they were treated,the control of its recurrence and metastasis is also the veryimportant issue to consider. So it is particularly important.to look a specific tumormarkers and research potential therapeutic targets for the treatment of liver cells. Recently,CDC25C protein is studied popularly,which belongs to the family ofCDC25protein kinase.It plays an important role which controls the cell cycle inG2/M phase transition.At the same time, it also plays an important role in the mitosisphase.In the recent years,with the more and more research,people find its highexpression level in many carcinomas,such as kidney cancer、gastric cancer、breastcancer.According further evidence,people found that its overexpression can lead tothe occurrence of tumor.Furthermore,people found that its overexpression has arelevant of the malignant degree、distant metastasis、diameter size, and so on. It rarelymake the news that it expresses in hepatocellular carcinoma.Claudin-6protein belongs to Claudins family, Claudins protein are importantparts of cell tight junction. It can be as a molecular flow barriers between epithelialcells. In addition, they also are able to maintain cell polarity、adhesion of cells, cellmembrane permeability, transport of cells and regulate cell proliferation anddifferentiation,too. The study also found that its expression of abnormal has closerelationship with the occurrence and development of tumor. And its high and lowexpression are likely to affect the abnormal cells. In other words, its overexpress orlowerexpress in the organization are likely to cause the integrity of the structuredamage, leading to the occurrence of tumor development. So, in hepatocellularcarcinoma, CLDN6protein is a rise or fall, our country has not reported in theliterature. Therefore studying of the CLDN6protein expression in hepatocellularcarcinoma (HCC)has an important and positive significance.Therefore, in this study, we will detect CDC25C protein and CLDN6proteinin normal liver cells, tissue adjacent to carcinoma and hepatocellular carcinoma tissueby using immunohistochemical method. Then we carry out a follow-up in patientswhose hepatocellular carcinoma specimens correspond, statistics of its prognosis. Inthe final, analyze two kinds of protein in hepatocellular carcinoma tissue expressionand clinical significance.ObjectiveHere,we detect the cell division cycle25homologous protein C protein (CDC25C) and tight junction proteins Claudin-6(CLDN6) in human hepatocellularcarcinoma tissue、tissue adjacent to carcinoma and normal liver tissue, discussingwith the role and significance of CDC25C and CLDN6two proteins in the occurrenceand development of HCC.Materials and methodsWe collected58cases of HCC specimens which resect from August2011toApril2012in the first affiliated hospital of zhengzhou university through surgicaltechnology.And all patients were discovered at fist time. They were confirmed bypathology after surgery.Before operation,they were not go through any cancertreatment.For all patients,we made the follow-up until june2013.Then we calculatethe disease-free survival time in month. This experiment used disease-free survivaltime to analyze the median disease-free survival time of58patients with HCC. Andwe made another24cases tissue adjacent to carcinoma and18cases of normal livertissues as control group. staining Then detect CDC25C and CLDN6in58cases ofhepatocellular carcinoma tissue,24cases of tissue adjacent to carcinoma and18casesof normal liver tissue by adopting the method of immunohistochemical(SABCmethod).We used SPSS17.0statistical software to process data, after, the comparisonof two rate involves using chi-square test, correlation analysis using Pearsoncorrelation detection, the disease-free survival data analysis using Kaplan-Meiermethod,and parallel log-rank test. In addition, we analyze the expression of twoproteins the relationship in clinical pathological features.Result1．Immunohistochemical results: In the detection of tissues,we can see a lot ofthe color of the shades of tan particles for CDC25C and CLDN6protein which existsin cytoplasm and nuclei. CDC25C in hepatocellular carcinoma tissue, the tissueadjacent to carcinoma and normal liver tissue expresses positive rate of86.2%,45.8%and11.1%, respectively. Expressing differences have statistical significance(P＜ 0.05).CLDN6in hepatocellular carcinoma tissue, the tissue adjacent to carcinoma andnormal liver tissue expresses positive rate of86.2%,45.8%and11.1%, respectively.Expressing differences have statistical significance(P＜0.05).2．Statistical software analysis results: CDC25C expression in HCC tissue havea relation to hepatitis B surface antigen (HBsAg), tumor diameter size and degree oftumor differentiation (P＜0.05). CDC25C expression in HCC tissue have a relation totumor diameter size(P＜0.05). In CDC25C positive and negative groups,the mediandisease-free survival times are12and15months, respectively and the difference wasstatistically significant (P＜0.05). In CLDN6positive and negative groups,themedian disease-free survival times are12months and14months respectively, thedifference was statistically significant (P＜0.05). CDC25C has a positive correlationwith CLDN6and the difference was statistically significant （r=0.359，P＜0.05）.Conclusion1.CDC25C and CLDN6proteins overexpressed in hepatocellular carcinomatissues.Also,the expression of CDC25C and CLDN6proteins in liver cancerwere passively correlated.2. The expression of CDC25C protein in hepatocellular carcinoma tissue wasrelated to hepatitis B surface antigen (HBsAg), tumor size and tumordifferentiation degree. The expression of CLDN6protein in hepatocellularcarcinoma (HCC) organizations was related to tumor diameter size. CDC25Cand CLDN6proteins have important significance in invasive of HCC andprognosis judgment. Regard to median disease-free survival time,HCC patientswhose CDC25C are negative is longer than HCC patients whose CDC25CCDC25C are positive and HCC patients whose CLDN6are negative is longerthan HCC patients whose CLDN6are positive.